CHO Pharma, Inc. (TPEX:6586)

Market Cap	24.50B +207.0%
Revenue (ttm)	1.71M -46.9%
Net Income	-268.04M
EPS	-1.26
Shares Out	214.01M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	200
Open	112.50
Previous Close	114.50
Day's Range	112.50 - 114.50
52-Week Range	22.75 - 148.50
Beta	0.77
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About CHO Pharma

CHO Pharma, Inc., engages in research and development of biotechnology in Taiwan. It develops glycoengineering platform technologies, including SAR-based glycoengineered biobetters; glycosite-specific antibody-drug conjugates (ADCs); novel antibodies and vaccines targeting novel carbohydrate antigens; and programs using its glycoengineering technologies. The company also provides CHOptimax, an in vitro enzymatic one-pot process that converts naked antibodies into glycoengineered biobetter or ADC. In addition, the company develops CHO-H01, which...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6586

Financial Performance

In 2025, CHO Pharma's revenue was 1.43 million, a decrease of -60.03% compared to the previous year's 3.58 million. Losses were -290.01 million, 36.6% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 19, 2026

Data Sources Report a data error